- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00731783
Staphylococcus Aureus Decolonization Study (SuDS)
Household vs. Individual Approach to Decolonization of Community-acquired Methicillin-resistant Staphylococcus Aureus.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Methicillin-resistant Staphylococcus aureus (MRSA) was once uniformly associated with hospital-acquired infections; however, MRSA strains have emerged that thrive outside the hospital environment, causing significant morbidity and mortality among immunocompetent individuals, leading to their designation as community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA).
CA-MRSA has become a major source of morbidity and mortality in our pediatric population. An important prerequisite for S. aureus infection may be nasal carriage of the organism. A variety of decolonization strategies have been used for infection prophylaxis, primarily in patients undergoing hemodialysis or surgery, with varying results. However, there are no published randomized eradication trials evaluating the decolonization and prevention of CA-MRSA infections in immunocompetent children in the outpatient setting. While the transmission of CA-MRSA within households has been reported, its contribution to recurrent CA-MRSA infection among household members is undetermined. The investigators hypothesize that spread of CA-MRSA among household members leads to recolonization or failure of decolonization in children undergoing eradication efforts.
Specific Aim: In pediatric patients presenting with a MRSA skin or soft tissue infection, compare the effectiveness of decolonization measures performed by an entire household in comparison to measures directed at the index patient alone. The investigators will conduct a randomized, controlled trial to test the hypothesis that decolonization measures performed by the entire household, specifically application of intranasal mupirocin ointment and bathing with chlorhexidine liquid soap, in addition to education and basic hygiene interventions, will be twice as effective in eradicating CA-MRSA carriage in the index patient than if the measures are performed only by the index patient.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- St. Louis Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Screening:
- Children aged 6 months to 21 years presenting with an active skin or soft tissue infection.
Enrollment:
- Positive MRSA culture from the abscess and from either the axilla, anterior nares or groin area (signifying both infection and colonization with MRSA).
Exclusion Criteria:
- Infants less than 6 months of age
- Dialysis or residence in a long term care facility over the past year
- Use of chlorhexidine or mupirocin in the past one month
- Pregnancy
- Immunodeficiency
- History of an adverse reaction to chlorhexidine or mupirocin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Index patient only
Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
|
Apply ointment to the anterior nares twice daily for 5 days.
Other Names:
Bathe with liquid soap daily for 5 days.
Other Names:
Follow key hygiene tips indefinitely. Tips are:
|
|
Active Comparator: Household
All members of the household (over the age of 6 months) will be asked to follow the study protocol.
|
Apply ointment to the anterior nares twice daily for 5 days.
Other Names:
Bathe with liquid soap daily for 5 days.
Other Names:
Follow key hygiene tips indefinitely. Tips are:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures
Time Frame: 1 month after enrollment.
|
Eradication is defined as the absence of S. aureus carriage at the 3 sampled body sites (anterior nares, axilla, inguinal folds) of the index patient.
|
1 month after enrollment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Index Patients Eradicated of S. Aureus Carriage - 3 Month After Performing Decolonization Measures
Time Frame: 3 month after enrollment.
|
Eradication is defined as the absence of S. aureus carriage at the 3 sampled body sites (anterior nares, axilla, inguinal folds) of the index patient.
|
3 month after enrollment.
|
|
Number of Index Patients Eradicated of S. Aureus Carriage - 6 Month After Performing Decolonization Measures
Time Frame: 6 month after enrollment.
|
Eradication is defined as the absence of S. aureus carriage at the 3 sampled body sites (anterior nares, axilla, inguinal folds) of the index patient.
|
6 month after enrollment.
|
|
Number of Index Patients Eradicated of S. Aureus Carriage - 12 Month After Performing Decolonization Measures
Time Frame: 12 month after enrollment.
|
Eradication is defined as the absence of S. aureus carriage at the 3 sampled body sites (anterior nares, axilla, inguinal folds) of the index patient.
|
12 month after enrollment.
|
|
Recurrence of CA-MRSA Skin or Soft Tissue Infection - 1 Month After Enrollment.
Time Frame: 1 month after enrollment
|
Recurrence of CA-MRSA Skin or Soft Tissue Infection
|
1 month after enrollment
|
|
Recurrence of CA-MRSA Skin or Soft Tissue Infection - 3 Month After Enrollment.
Time Frame: 3 month after enrollment
|
Recurrence of CA-MRSA Skin or Soft Tissue Infection
|
3 month after enrollment
|
|
Recurrence of CA-MRSA Skin or Soft Tissue Infection - 6 Month After Enrollment.
Time Frame: 6 month after enrollment
|
Recurrence of CA-MRSA Skin or Soft Tissue Infection
|
6 month after enrollment
|
|
Recurrence of CA-MRSA Skin or Soft Tissue Infection - 12 Month After Enrollment.
Time Frame: 12 month after enrollment
|
Recurrence of CA-MRSA Skin or Soft Tissue Infection
|
12 month after enrollment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stephanie A Fritz, MD, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Inflammation
- Disease Attributes
- Connective Tissue Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Suppuration
- Skin Diseases, Bacterial
- Infections
- Communicable Diseases
- Abscess
- Cellulitis
- Skin Diseases, Infectious
- Staphylococcal Skin Infections
- Furunculosis
- Staphylococcal Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Enzyme Inhibitors
- Dermatologic Agents
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Disinfectants
- Mupirocin
- Chlorhexidine
- Chlorhexidine gluconate
Other Study ID Numbers
- 3177 38145
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.